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A B S T R A C T
Rasagiline is a propargylamine and irreversible monoamine oxidase (MAO) B inhibitor used for the
treatment of Parkinson’s disease (PD). It has demonstrated neuroprotective properties in laboratory
studies. Current concepts of PD aetiopathogenesis include the role of alpha-synuclein, protein
aggregation, free radical metabolism and mitochondrial dysfunction in contributing to cell death. We
have used a combination of alpha-synuclein and free radicalmediated toxicity in a dopaminergic cell line
to provide a model of nigral toxicity in order to investigate the potential molecular mechanisms that
mediate rasagiline protection. We demonstrate that rasagiline protects against cell death induced by the
combination of free radicals generated by paraquat and either wild-type or A53T mutant alpha-
synuclein over-expression. This protection was associated with a reduction in caspase 3 activation, a
reduction in superoxide generation and a trend to ameliorate the fall in mitochondrial membrane
potential. Rasagiline induced an increase in cellular glutathione levels. The results support a role for
rasagiline in protecting dopaminergic cells against free radical mediated damage and apoptosis in the
presence of alpha-synuclein over-expression. The data are of relevance to the interpretation of the
potential mechanisms of action of rasagiline in explaining the results of diseasemodiﬁcation trials in PD.
 2010 Elsevier Ltd.
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Parkinson’s disease (PD) is a progressive multi-centric neuro-
degenerative disease whose predominant early diagnostic features
are secondary to the loss of nigrostriatal dopaminergic neurons.
The current concepts of aetiopathogenesis of PD incorporate
genetic and environmental inﬂuences (Schapira, 2006, 2008a).
Alpha-synuclein appears to be important in both genetic and
sporadic forms of PD. Point mutations, e.g. A53T, A30P and
multiplications have been identiﬁed as causes of familial PD, and in
the latter the level of protein expression relates to age of onset: the
greater the expression, the younger the onset of PD (Fuchs et al.,
2007). Polymorphisms of the alpha-synuclein promoter region that
increase protein expression enhance the risk for the PD (Ross et al.,
2008). The observation that alpha-synuclein is a major constituent
of Lewy bodies, indicates its importance in the pathology of
sporadic PD. The mechanisms by which alpha-synuclein toxicity
are mediated are not fully understood, but are thought to include
free radical mediated damage, mitochondrial dysfunction and the
promotion of cell death by apoptosis (Schapira, 2006).
Rasagiline is a propargylamine and an irreversible inhibitor of
monoamine oxidase B (MAOB). This compound has demonstrated* Corresponding author. Tel.: +44 020 7830 2012; fax: +44 020 7472 6829.
E-mail address: a.schapira@medsch.ucl.ac.uk (A.H.V. Schapira).
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Open access under CC BY license. protective properties in vitro against a number of dopaminergic
toxins including the nitric oxide donor 3-morpholinosydnonimi-
nehydrochloride (SIN-1), glutamate, 6-hydroxydopamine (6-
OHDA), 1-methyl-4-phenyl pyridinium (MPP+), b-amyloid, tetra-
hydroisoquinoline, and serum and growth factor deprivation (for
reviews see Mandel et al., 2005; Schapira, 2008b). This protection
is not dependent upon the MAOB inhibitory action of rasagiline as
the MAO inactive S-enantiomer of rasagiline is as potent in
protection studies as the active form, and protection is seen in cells
that do not express MAOB (Maruyama et al., 2003; Youdim et al.,
2001a,b; Youdim and Weinstock, 2001). Rasagiline exerts its
protection in certain of these models via an anti-apoptotic action
that may be mediated by activation of Bcl-2 and Bcl-xL and the
protein kinase C/mitogen-activated protein kinase (PKC/MAPK)
pathway, and down-regulation of pro-apoptotic molecules such as
Bax and Bad (Mandel et al., 2005; Youdim et al., 2005a,b).
Aminoindan, the major metabolite of rasagiline has no MAOB
inhibitory action but has been reported to exert some protective
effects (Bar-Am et al., 2007; Chen et al., 2007).
Drugs currently available for the treatment of PD are
predominantly directed to enhancing dopaminergic function and
providing relief of motor symptoms. Considerable effort is now
focussed on developing compounds that will slow or stop
progression of neurodegeneration (Olanow et al., 2008; Schapira,
1999). We hypothesized that given the actions of rasagiline in
protecting against dopaminergic toxins, this molecule would be
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alpha-synuclein.
2. Materials and methods
2.1. Cell culture
SHSY5Y cells were cultured in a 1:1 mixture of Dulbecco’s modiﬁed Eagle’s
medium and Ham’s F12 medium supplemented with 10% fetal bovine serum
(Labtech, East Sussex, UK), 0.01 mM nonessential amino acids, 100 U/ml penicillin
and 100mg/ml streptomycin (all from Invitrogen, San Diego, CA), at 37 8C under
humidiﬁed 5% CO2 atmosphere. Two SHSY5Y cell lines each stably over-expressing
similar levels of wild-type (WTSyn) or mutant (A53TSyn) alpha-synuclein, and the
controlled cells containing the empty expression plasmid, were maintained in
400 mg/ml G418 (PAA labs, Pasching, Austria), and their characterisation has been
previously described (Chau et al., 2009).
2.2. Chemicals
Paraquat, rotenone, Triton X-100, and H2 were purchased from Sigma–Aldrich
(St. Louis, MO). Rasagiline was provided by Teva.
2.3. Treatments
The incubation schedules of rasagiline and paraquat are illustrated in Fig. 1.
2.4. Measurement of cell death (LDH assays)
Percentage release of lactate dehydrogenase (LDH) was measured by the
Promega 96 CytoTox assay kit (Madison, WI). In brief, SHSY5Y cells were seeded
into 24-well plates and left to grow to 60% conﬂuence, achieved typically within
48 h from seeding at 40%. The medium was replaced by culture medium lacking
-red. After incubations the medium was measured for LDH release, whereas in a
duplicate well cells were lysed by the addition of Triton X-100 (to a ﬁnal of 1%)
to measure total LDH. After mixing the samples with the substrate and
incubated at room temperature for 30 min, OD was measured using a plate
reader (Biorad, Hercules, CA) with ﬁlter of 492 nm. The percentage of LDH
release was calculated from the medium and total values corrected for
background.
2.5. Measurement of capase-3 activity
SHSY5Y cells grown on 12-well plates were incubated in phenol-red-free
medium. Cells collectedwere lysed according to themanufacturer’s instruction and
protein level of lysates determined by BCA protein assays kit (Pierce, Rockford, IL).
Lysates of equal amount of protein were mixed with reaction buffer and caspase-3
substrate Z-DEVD-R110 (Molecular Probes, Eugene, OR) into a 96-well plate
incubated at room temperature for 1 h and read using a ﬂuorescence plate reader
(Bio-Tek’s Synergy HTmodel,Winooski, VT), with excitation (Ex) and emission (Em)
wavelengths of 485  20 nm and 528  20 nm.
2.6. Measurement of mitochondrial membrane potential (TMRM staining)
To SHSY5Y cells grown on 24-well plates was added tetramethyl rhodamine
methyl ester (25mM Molecular Probes), and incubated at 37 8C for 30 min.
Attached cells were washed and the TMRM mitochondrial staining was quantiﬁed
by a scanning function of 3  3 matrix to the bottom of the well, using the Synergy
HT microplate reader set as 530  25 nm Ex/590  35 nm Em. To a duplicate well
treated in the same manner, total LDH was determined as above and this reading was
used to correct for cell number.Fig. 1. Schematic illustration on the various combinations of incubation between
rasagiline and paraquat.2.7. Measurement of reactive oxygen species (DHE staining)
SHSY5Y cells seeded onto 24-well plates were stained with growth medium
without FBS containing 20mMdihydroethidium (DHE, Molecular Probes) for 30 min
at 37 8C. Adherent cells were washed and intracellular ethidium (oxidised product of
DHE), was measured by scanning the bottom of the well by a 5  5 matrix, using the
Synergy HT microplate reader with an excitation and emission wavelength of
530  25 nm and 590  35 nm. The DHE taken up by the cells was fully oxidised by
additionof 88 mMH2O2 and50mg/ml peroxidase in the presence of 1% TritonX-100 and
further incubated at 378C for 1 h, before measuring ﬂuorescence again. Percentage
oxidised DHE represents the percentage of oxidised DHE over total DHE taken up.
2.8. Measurement of glutathione content
Intracellular glutathione concentration was measured by a kit provided by
Calbiochem (San Diego, CA), using a metaphosphoric acid lysate of SHSY5Y cells
collected from a 10 cm plate. BCA protein assay was performed on the lysate to
correct for protein content.
2.9. Statistical analysis
Independent experimental repeats were carried out as indicated, and the results
are presented as mean values  standard error of mean (error bars). Unpaired t test,
one-way ANOVA followed by Dunnett or Tukey–Kramer’s post-test analysis was
performed. A p value of 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Rasagiline reduced cell death induced by paraquat and alpha-
synuclein over-expression
Incubation of the free radical inducing agent paraquat (300mM)
for 48 h induced a signiﬁcant increase in cell death in SHSY5Y cells
(from 9% to 49%, p < 0.0001, 22 degrees of freedom, F = 13.033 by
unpaired t test, Fig. 2A). When rasagiline (0–10mM) was added
24 h before (pre-incubation) and for 48 h with paraquat (co-
incubation) cell death was reduced in a dose dependent manner,
reaching signiﬁcance at 10 mMwith a reduction of 19% (p < 0.05, 4
degrees of freedom between treatments and 45 degree of freedomFig. 2. Rasagiline reduced death induced by paraquat in SHSY5Y cells, and cells
over-expressing wild-type and A53T mutation of alpha-synuclein. Paraquat
exposure for 48 h in (A) normal SHSY5Y cells, and (B) 2 independent cell lines
each expressing similar levels of wild-type (WT) and mutant alpha-synuclein
(A53T), and the control SHSY5Y cells harbouring the empty expression plasmid. Cell
death measured by LDH release and expressed as mean  standard error of mean, of
at least 6 experimental repeats. Data of both cell lines from each model are combined.
Signiﬁcance determined by unpaired t test, one-way ANOVA followed by Dunnett and
Tukey–Kramer’s post-test accordingly.
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Dunnett’s post-test, Fig. 2A). Pre-incubation or co-incubation of
rasagiline alone did not decrease cell death (data not shown).
Based upon these preliminary studies, 10 mM rasagiline and
300 mM paraquat were used in all further studies. The dose of
paraquat selected was based upon its ability to induce moderate
cell death at a level that could potentially be reversed by a
protective agent.
Stable over-expression of either wild-type (WTSyn) or mutant
(A53TSyn) alpha-synuclein in SHSY5Y cells resulted over a short
time scale (48–72 h) in small but signiﬁcant increases in cell death
under basal conditions (both p < 0.001, 2 degrees of freedom
between treatments and 65 degree of freedom between residuals,
F = 18.934, by one-way ANOVA followed by Tukey–Kramer’s post-
test, Fig. 2B). The addition of 10 mM rasagiline for 72 h had no
effect on baseline cell death in these cells (Fig. 2B). Incubationwith
300 mM paraquat over 48 h caused a signiﬁcant increase in death
in all cell lines tested (p < 0.001 for all lines relative to untreated
cells; 3 degrees of freedom between treatments and 101 degree of
freedom between residuals, F = 78.392 for control cells; 3 degrees
of freedombetween treatments and 77 degree of freedombetween
residuals, F = 77.313 for WTSyn cells; 3 degrees of freedom
between treatments and 100 degree of freedombetween residuals,
F = 67.985 for A53TSyn cells; all by one-way ANOVA followed by
Tukey–Kramer’s post-test). The A53TSyn cells were signiﬁcantly
more sensitive to the paraquat treatment compared to both control
SHSY5Y and WTSyn cells (p < 0.001 and 0.05 respectively, 2
degrees of freedom between treatments and 99 degree of freedom
between residuals, F = 8.429, by one-way ANOVA followed by
Tukey–Kramer’s post-test, Fig. 2B). Rasagiline (10mM pre- and co-
incubation) signiﬁcantly decreased themean cell death induced by
paraquat treatment in all cell lines (by 19%, 49% and 42% in control,
WTSyn and A53TSyn cells respectively, all p < 0.001; degrees of
freedom and F values as above after one-way ANOVA followed by
Tukey–Kramer’s post-test), such that death in the A53TSyn cells
was now comparable to the other lines (Fig. 2B).
3.2. Rasagiline decreased paraquat-induced caspase-3 activation
Caspase-3 activity under basal conditions was signiﬁcantly
greater in the mutant A53TSyn cells compared to both control and
WT SHSY5Y lines (both p < 0.05, 2 degrees of freedom between
treatments and 61 degree of freedom between residuals, F = 4.812,
by one-way ANOVA followed by Tukey–Kramer’s post-test, Fig. 3).
Caspase-3 activity was increased by exposure to paraquat in
control, WTSyn and A53TSyn expressing SHSY5Y cells (p > 0.001
for all 3 groups; 3 degrees of freedom between treatments and 100
degrees of freedom between residuals, F = 119.14 for control cells;Fig. 3. Rasagiline decreased caspase-3 activated by paraquat exposure in empty
vector SHSY5Y cells and cells expressingwild-typeorA53T alpha-synuclein. Caspase-
3 activitywasmeasuredby cleavage of Z-DEVD-R110 to releaseﬂuorescence thatwas
corrected for protein level. Shown is themean ﬂuorescence standard error ofmean,
of 9 experiments. One-way ANOVA followed by Tukey–Kramer’s post-test was carried
out to compare between treatments.3 degrees of freedom between treatments and 56 degrees of
freedom between residuals, F = 33.679 for WTSyn cells; 3 degrees
of freedombetween treatments and 73 degree of freedombetween
residuals, F = 22.205 for A53TSyn cells; all by one-way ANOVA
followed by Tukey–Kramer’s post-test) with no signiﬁcant
difference between the lines. Rasagiline treatment (10 mM pre-
and co-incubation) signiﬁcantly reduced the paraquat-induced
caspase activity in the control andWTSyn expressing SHSY5Y cells
(by 15%, p < 0.001 and 21%, p < 0.05 respectively; degrees of
freedom and F values as above after one-way ANOVA followed by
Tukey–Kramer’s post-test). A 15% reduction was observed in
A53TSyn lines although this did not reach statistical signiﬁcance.
Mitochondrial membrane potential was similar in all the
untreated cell lines (Fig. 4). Following paraquat treatment the
membrane potential decreased in all lines, butwithmost reduction
seen in the mutant A53TSyn cells (to 67% in A53TSyn; 47% in
control and 54% in WTSyn, all p > 0.001; 3 degrees of freedom
between treatments and 81 degree of freedom between residuals,
F = 10.339 for control cells; 3 degrees of freedom between
treatments and 81 degrees of freedom between residuals,
F = 14.08 for WTSyn cells; 3 degrees of freedom between
treatments and 45 degree of freedom between residuals,
F = 7.323 for A53TSyn cells; all by one-way ANOVA followed by
Tukey–Kramer’s post-test). The reduced membrane potential seen
in the A53TSyn cells was signiﬁcantly greater than in control cells
(p < 0.05, 2 degrees of freedom between treatments and 50 degree
of freedom between residuals, F = 3.283, by one-way ANOVA
followed by Tukey–Kramer’s post-test, Fig. 4). There was a trend
for the addition of 10 mM rasagiline to restore the membrane
potential in all cells, but this did not reach statistical signiﬁcance.
However, there was also no longer any signiﬁcant difference in the
membrane potential between control and A53TSyn cells (Fig. 4).
3.3. Rasagiline reduced free radical generation and increased
glutathione levels
In untreated cells, there was a small but signiﬁcant increase in
free radical generation as measured by DHE in A53TSyn cells
compared toWTSyn cells, but not compared to controls (p < 0.05,
2 degrees of freedom between treatments and 100 degree of
freedom between residuals, F = 4.312, by one-way ANOVA
followed by Tukey–Kramer’s post-test, Fig. 5). Paraquat treatment
induced a signiﬁcant increase in superoxide production (in-
creased by 142%, 306% and 462% in control, WTSyn and A53TSyn
cells respectively, all p < 0.001; 3 degrees of freedom between
treatments and 122 degree of freedom between residuals,
F = 88.774 for control cells; 3 degrees of freedom between
treatments and 140 degree of freedom between residuals,Fig. 4. Rasagiline effect on mitochondrial membrane potential (Cm) reduction
caused by paraquat in empty vector SHSY5Y cells and cells expressing wild-type or
A53T alpha-synuclein. Mitochondrial membrane potential wasmeasured by TMRM
staining and corrected for cell number by total LDH level. Mean TMRM
signal  standard error of mean of 5 experiments, is illustrated. One-way ANOVA
followed by Tukey–Kramer’s post-test was carried out by comparing between
treatments.
Fig. 5. Rasagiline effect on the oxidation of dihydroethidium (DHE) as a
measurement of reactive oxygen species induced by paraquat in empty vector
SHSY5Y cells and cells expressing wild-type or A53T alpha-synuclein. Oxidised
DHE, followed by the total DHE (after addition of peroxidase, H2O2 and Triton X-
100), was measured and expressed as % oxidised DHE, of the mean  standard error
of mean of 8 experiments. One-way ANOVA followed by Tukey–Kramer’s post-test was
used to compare treatments.
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treatments and 140 degree of freedom between residuals,
F = 406.55 for A53TSyn cells; all by one-way ANOVA followed
by Tukey–Kramer’s post-test) compared to the respective
untreated cell lines. Furthermore, the increase in DHE oxidation
in A53TSyn cells was signiﬁcantly greater than that seen in either
control or WTSyn cells (both p < 0.001, 2 degrees of freedom
between treatments and 101 degree of freedom between
residuals, F = 177.43, by one-way ANOVA followed by Tukey–
Kramer’s post-test, Fig. 5). Rasagiline (10 mM pre- and co-
incubation) reduced DHE oxidation in all 3 lines (by 22%, 40%
and 41% in control, WTSyn and A53TSyn cells respectively, all
p < 0.001 compared to paraquat alone; degrees of freedom and F
values as above after one-way ANOVA followed by Tukey–
Kramer’s post-test). However, although signiﬁcantly reduced in
the presence of rasagiline, DHE oxidation was still signiﬁcantly
higher in the A53TSyn cells compared to the control andWT cells
(both p < 0.001, 2 degrees of freedom between treatments and
101 degree of freedom between residuals, F = 54.5, by one-way
ANOVA followed by Tukey–Kramer’s post-test, Fig. 5).
Incubation of rasagiline for 24 h was found to increase
glutathione levels signiﬁcantly in SHSY5Y cells (p < 0.05, 4 degrees
of freedom between treatments and 38 degree of freedombetweenFig. 6. Inﬂuence of rasagiline on glutathione levels in SHSY5Y cells. SHSY5Y cells
were incubated with increasing level of rasagiline for 24 h and glutathione content
was measured that was corrected for protein level. Shown is a summary of 7
experiments its mean  standard error of mean (signiﬁcance determined by ANOVA
followed by Dunnett post-test).residuals, F = 2.684, by one-way ANOVA followed by Dunnett’s
post-test; Fig. 6).
4. Discussion
Alpha-synuclein is themajor protein component of Lewy bodies
and Lewy neurites in PD brain (Spillantini et al., 1997) and both
point mutations and multiplications of the alpha-synuclein gene,
as well as polymorphisms that increase expression, have been
associated with familial PD (Fuchs et al., 2007; Ross et al., 2008).
Conversely, deletion of alpha-synuclein in mice protects dopami-
nergic neurons against both 6-hydroxydopamine and MPTP (1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine) toxicity (Dauer
et al., 2002; Varez-Fischer et al., 2008). Several studies support a
role for oxidative and/or nitrative stress in alpha-synuclein
modiﬁcation and/or aggregation (Giasson et al., 2000). We have
previously shown that increased expression of A53Tmutant alpha-
synuclein increases susceptibility to dopamine toxicity, potentially
by increasing cytosolic dopamine (Tabrizi et al., 2000). A recent
report has demonstrated that a combination of increased WT
alpha-synuclein expression, elevated cytoplasmic calcium and
dopamine levels enhances selective dopaminergic cell death
(Mosharov et al., 2009). Thus, our model incorporating both free
radical generation and alpha-synuclein expression provides a
useful tool to investigate the interaction of pathogenetic pathways
in PD and potential targets for neuroprotection. We have recently
used this model to show that the dopamine receptor agonist
cabergoline is able to protect against alpha-synuclein toxicity, an
effect partially mediated via dopamine receptors (Chau et al.,
2009).
Rasagiline is a propargylamine, one of a group of molecules
considered to have neuroprotective potential in PD (Schapira,
2008a). The propargylamine selegiline has demonstrated neu-
roprotective properties in vitro, in vivo and possibly in PD
patients although there remains debate regarding its efﬁcacy in
the latter (The Parkinson Study Group, 1993). It is notable that
selegiline is metabolised to amphetamines which can them-
selves inhibit the protective action of the parent molecule (Bar
et al., 2004; Bar-Am et al., 2004). TCH346, another propargy-
lamine was protective in numerous pre-clinical models of PD,
but failed to demonstrate any protective effect in PD patients,
although this may reﬂect errors in clinical trial design (Olanow
et al., 2006). Rasagiline is metabolised to aminoindan, which
may itself have protective properties through anti-apoptotic
actions (Bar-Am et al., 2007). Rasagiline has demonstrated the
capacity to protect a variety of neuronal types against a range of
toxic processes in vitro and in animal models (Mandel et al.,
2005). We have explored the possible mechanisms of action of
rasagiline that might mediate a protective action against cell
death in a cell model that combines important features of PD
pathogenesis.
In our SHSY5Y WTSyn and A53TSyn stable over-expression
models, there was an increase in cell death compared to control
even over the relatively short time course of 48 h. This innate
toxicity of alpha-synuclein expression has been seen in a variety
of cell lines and animal models (reviewed in Olanow and
Kordower, 2009). Paraquat caused a signiﬁcant increase in death
in all our cell lines accompanied by increased free radical
generation, reduced mitochondrial membrane potential and
increased caspase activation. The A53T mutant cells were
signiﬁcantly more sensitive to paraquat, indicating a synergistic
and detrimental action of free radicals in these cells. The
explanation for this synergistic effect on toxicity is not certain,
but several studies have suggested that oxidative stress causes
accumulation alpha-synuclein protoﬁbrils (Conway et al., 2001)
and promotes oligomerisation (Norris et al., 2003).
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combined toxicity model. The reduction in caspase-3 activation
and the trend to protect against a fall in mitochondrial membrane
potential are both in line with an action of rasagiline via an
inhibition of mitochondria-mediated apoptosis. This is in agree-
ment with previous studies on rasagiline (Mandel et al., 2005).
Furthermore, we demonstrated that rasagiline can increase
cellular GSH levels and reduce superoxide generation in the
paraquat–alpha-synuclein model, suggesting that its protective
actions incorporate an anti-oxidant effect. The protective actions of
rasagiline were such that it was able to counter the additional
sensitivity to paraquat conferred by the expression of A53T alpha-
synuclein.
These in vitro studies conﬁrm a protective action of rasagiline
against a free radical generator and extend its potential efﬁcacy to
a combined genetic-toxin model: WT or mutant alpha-synuclein
over-expression. Our results support the concept that free radical
generation can enhance alpha-synuclein toxicity and show for the
ﬁrst time that rasagiline can ameliorate this effect. It is of interest
that alpha-synuclein toxicity may be propagated beyond the host
cell (Desplats et al., 2009; Kordower et al., 2008; Li et al., 2008) and
it is possible that this may be enhanced in an oxidative
environment. The relevance of these observations to modiﬁcation
of the course of PD by rasagiline remains uncertain.
The in vitro and in vivo protective actions of rasagiline have led
to it being tested as a drug that might have potential to modify the
clinical course of PD. Rasagiline confers symptomatic beneﬁt in PD
patients by virtue of its monoamine oxidase B inhibition
(Parkinson Study Group, 2004). The results of the ADAGIO3
(attenuation of disease progression with rasagiline once-daily)
have recently been reported (Olanow et al., 2009). The 1 mg dose
met a series of three hierarchical end points including slowing the
rate of deterioration inmotor function in those randomised to drug
versus placebo, a better motor outcome at 18 months and no
convergence of the rates of progression in the second 9 months of
the study.
The interpretation of the ADAGIO results is complex (Olanow
et al., 2009; Schapira, 2009) but include inter alia the possibility of a
true neuroprotective effect. The ability of rasagiline to protect
against paraquat–alpha-synuclein toxicity in our model, at least in
part through anti-oxidant and anti-apoptotic roles, is of interest in
this context. Our results cannot conﬁrm or support a neuroprotec-
tive role for rasagiline in PD patients, but do nevertheless provide a
potential mechanism of action for a putative protective effect.
Conﬂicts of interest
A.H.V. Schapira has received honoraria for contributions to
educational symposia and for the provision of advice in the
development of rasagiline.
Acknowledgements
This work was supported in part by Teva Pharmaceutical
Industries Ltd. and H. Lundbeck A/S Pharmaceuticals, the Kattan
Trust and the Parkinson’s disease Society UK.
We thank Drs. Jan-Willem Taanman and Mike Cleeter for
helpful discussions.
References
Bar, A.O., Amit, T., Youdim, M.B., 2004. Contrasting neuroprotective and neurotoxic
actions of respective metabolites of anti-Parkinson drugs rasagiline and selegi-
line. Neurosci. Lett. 355, 169–172.Bar-Am, O., Amit, T., Youdim, M.B., 2007. Aminoindan and hydroxyaminoindan,
metabolites of rasagiline and ladostigil, respectively, exert neuroprotective
properties in vitro. J. Neurochem. 103, 500–508.
Bar-Am, O., et al., 2004. Regulation of protein kinase C by the anti-Parkinson drug,
MAO-B inhibitor, rasagiline and its derivatives, in vivo. J. Neurochem. 89, 1119–
1125.
Chau, K.Y., et al., 2009. Protection against paraquat and A53T alpha-synuclein
toxicity by cabergoline is partially mediated by dopamine receptors. J. Neurol.
Sci. 278, 44–53.
Chen, J.J., Swope, D.M., Dashtipour, K., 2007. Comprehensive review of rasagiline, a
second-generation monoamine oxidase inhibitor, for the treatment of Parkin-
son’s disease. Clin. Ther. 29, 1825–1849.
Conway, K.A., et al., 2001. Kinetic stabilization of the alpha-synuclein protoﬁbril by
a dopamine–alpha-synuclein adduct. Science 294, 1346–1349.
Dauer, W., et al., 2002. Resistance of alpha-synuclein null mice to the Parkinsonian
neurotoxin MPTP. Proc. Natl. Acad. Sci. U.S.A. 99, 14524–14529.
Desplats, P., et al., 2009. Inclusion formation and neuronal cell death through
neuron-to-neuron transmission of alpha-synuclein. Proc. Natl. Acad. Sci. U.S.A.
106, 13010–13015.
Fuchs, J., et al., 2007. Phenotypic variation in a large Swedish pedigree due to SNCA
duplication and triplication. Neurology 68, 916–922.
Giasson, B.I., et al., 2000. Oxidative damage linked to neurodegeneration by
selective alpha-synuclein nitration in synucleinopathy lesions. Science 290,
985–989.
Kordower, J.H., et al., 2008. Lewy body-like pathology in long-term embryonic
nigral transplants in Parkinson’s disease. Nat. Med. 14, 504–506.
Li, J.Y., et al., 2008. Lewy bodies in grafted neurons in subjects with Parkinson’s
disease suggest host-to-graft disease propagation. Nat. Med. 14, 501–503.
Mandel, S., et al., 2005. Mechanism of neuroprotective action of the anti-Parkinson
drug rasagiline and its derivatives. Brain Res. Brain Res. Rev. 48, 379–387.
Maruyama, W., et al., 2003. Anti-apoptotic action of anti-Alzheimer drug, TV3326
[(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cho-
linesterase-monoamine oxidase inhibitor. Neurosci. Lett. 341, 233–236.
Mosharov, E.V., et al., 2009. Interplay between cytosolic dopamine, calcium, and
alpha-synuclein causes selective death of substantia nigra neurons. Neuron 62,
218–229.
Norris, E.H., et al., 2003. Effects of oxidative and nitrative challenges on alpha-
synuclein ﬁbrillogenesis involve distinct mechanisms of protein modiﬁcations.
J. Biol. Chem. 278, 27230–27240.
Olanow, C.W., et al., 2006. TCH346 as a neuroprotective drug in Parkinson’s disease:
a double-blind, randomised, controlled trial. Lancet Neurol. 5, 1013–1020.
Olanow, C.W., Kieburtz, K., Schapira, A.H., 2008. Why have we failed to achieve
neuroprotection in Parkinson’s disease? Ann. Neurol. 64 (Suppl. 2), S101–S110.
Olanow, C.W., Kordower, J.H., 2009. Modeling Parkinson’s disease. Ann. Neurol. 66,
432–436.
Olanow, C.W., et al., 2009. A double-blind, delayed-start trial of rasagiline in
Parkinson’s disease. N. Engl. J. Med. 361, 1268–1278.
Parkinson Study Group, 1993. Effects of tocopherol and deprenyl on the progression
of disability in early Parkinson’s disease. N. Engl. J. Med. 328, 176–183.
Parkinson Study Group, 2004. A controlled, randomized, delayed-start study of
rasagiline in early Parkinson disease. Arch. Neurol. 61, 561–566.
Ross, O.A., et al., 2008. Genomic investigation of alpha-synucleinmultiplication and
Parkinsonism. Ann. Neurol. 63, 743–750.
Schapira, A.H., 1999. Science, medicine, and the future: Parkinson’s disease. BMJ
318, 311–314.
Schapira, A.H., 2006. Etiology of Parkinson’s disease. Neurology 66, S10–S23.
Schapira, A.H., 2008a. Mitochondria in the aetiology and pathogenesis of Parkin-
son’s disease. Lancet Neurol. 7, 97–109.
Schapira, A.H., 2008b. Rasagiline in neurodegeneration. Exp. Neurol. 212, 255–257.
Schapira, A.H., 2009. Molecular and clinical pathways to neuroprotection of dopa-
minergic drugs in Parkinson disease. Neurology 72, S44–S50.
Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R., Goedert, M.,
1997. Alpha-synuclein in Lewy bodies. Nature 388, 839–840.
Tabrizi, S.J., et al., 2000. Expression of mutant alpha-synuclein causes increased
susceptibility to dopamine toxicity. Hum. Mol. Genet. 9, 2683–2689.
Varez-Fischer, D., et al., 2008. Modelling Parkinson-like neurodegeneration via
osmotic minipump delivery of MPTP and probenecid. J. Neurochem. 107, 701–
711.
Youdim, M.B., et al., 2001a. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective
and potent inhibitor of mitochondrial monoamine oxidase B. Br. J. Pharmacol.
132, 500–506.
Youdim, M.B., et al., 2001b. The anti-Parkinson drug rasagiline and its cholinester-
ase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in
cell culture and in vivo. Ann. N. Y. Acad. Sci. 939, 450–458.
Youdim, M.B., Weinstock, M., 2001. Molecular basis of neuroprotective activities of
rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoin-
dan-5-YL)-ethyl methyl carbamate]. Cell Mol. Neurobiol. 21, 555–573.
Youdim, M.B., Maruyama, W., Naoi, M., 2005a. Neuropharmacological, neuropro-
tective and amyloid precursor processing properties of selective MAO-B inhibi-
tor antiParkinsonian drug, rasagiline. Drugs Today (Barc.) 41, 369–391.
Youdim, M.B., et al., 2005b. Rasagiline: neurodegeneration, neuroprotection, and
mitochondrial permeability transition. J. Neurosci. Res. 79, 172–179.
